Posts By: pharmanewsdaily

Boston Scientific wraps up $4.2bn acquisition of BTG

Boston Scientific acquisition of BTG : US medical devices manufacturer Boston Scientific has wrapped up its previously announced $4.2 billion acquisition of UK-based healthcare company BTG. In November 2018, Boston Scientific reached an agreement on the terms of a recommended offer to acquire the British healthcare company for a cash consideration of 840 pence per […]

The post Boston Scientific wraps up $4.2bn acquisition of BTG appeared first on PharmaNewsDaily.com.

MERU clinical trial : AbbVie ends Rova-T program in lung cancer

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

The post MERU clinical trial : AbbVie ends Rova-T program in lung cancer appeared first on PharmaNewsDaily.com.

Surmodics wraps up enrollment for TRANSCEND trial of SurVeil DCB

Surmodics has wrapped up enrollment for the TRANSCEND clinical trial for the SurVeil drug-coated balloon (SurVeil DCB) for the treatment of peripheral artery disease (PAD) in the upper leg. Based in Minnesota, Surmodics is a provider of medical device and in vitro diagnostic technologies to the health care industry. The TRANSCEND clinical trial has enrolled […]

The post Surmodics wraps up enrollment for TRANSCEND trial of SurVeil DCB appeared first on PharmaNewsDaily.com.

Lilly bags Taltz FDA approval for ankylosing spondylitis

Taltz FDA approval : The US Food and Drug Administration (FDA) has approved US pharma giant Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults having active ankylosing spondylitis (AS). Also known as radiographic axial spondyloarthritis (r-axSpA), ankylosing spondylitis is a type of spondyloarthritis that affects the pelvic joints and […]

The post Lilly bags Taltz FDA approval for ankylosing spondylitis appeared first on PharmaNewsDaily.com.

Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn

Amgen acquisition of Otezla : Amgen has agreed to acquire global rights to Celgene’s psoriasis drug Otezla (apremilast) for $13.4 billion, which includes $2.2 billion in expected future cash tax benefits. The deal is being executed to pave way for regulatory approval for the previously announced Bristol-Myers Squibb acquisition of Celgene in a deal worth […]

The post Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn appeared first on PharmaNewsDaily.com.

ARKRAY USA rolls out Phazix Pill Swallowing Gel

ARKRAY USA has launched the Phazix Pill Swallowing Gel in the US, an over-the-counter pill swallowing gel to help people who find it difficult to swallow tablets, capsules, and powders. Phazix Pill Swallowing Gel, which is a thick, hyper-slippery smooth gel, has to be taken as nearly one teaspoon on a spoon along with one […]

The post ARKRAY USA rolls out Phazix Pill Swallowing Gel appeared first on PharmaNewsDaily.com.

Satsuma doses first patient in EMERGE clinical trial of STS101 in migraine

US biopharma company Satsuma Pharmaceuticals has dosed the first patient in its phase 3 EMERGE clinical trial of STS101 (dihydroergotamine (DHE) nasal powder) for migraine treatment. The EMERGE efficacy trial is a single-dose, double-blind, randomized, placebo-controlled, parallel-group study to be held in multiple centers. The phase 3 clinical trial will feature nearly 1,140 migraine patients […]

The post Satsuma doses first patient in EMERGE clinical trial of STS101 in migraine appeared first on PharmaNewsDaily.com.

V-Wave Interatrial Shunt System gets FDA breakthrough device status for HF

Israeli medical device company V-Wave has secured a breakthrough device designation from the US Food and Drug Administration (FDA) for its V-Wave Interatrial Shunt System for heart failure (HF). The minimally invasive, implanted interatrial shunt is being investigated by the Israeli medical device company in a global, randomized, controlled, double-blinded investigational device exemption (IDE) trial […]

The post V-Wave Interatrial Shunt System gets FDA breakthrough device status for HF appeared first on PharmaNewsDaily.com.

Imago Systems, Mayo Clinic to advance ICE Reveal for breast imaging

US medical imaging company Imago Systems and Mayo Clinic have signed a know-how license agreement to collaborate on breast imaging with the academic medical center to support clinical trial development and oversee the former’s reader studies for mammography. The multi-year agreement signed by the parties will focus on clinical trial support for the ICE Reveal […]

The post Imago Systems, Mayo Clinic to advance ICE Reveal for breast imaging appeared first on PharmaNewsDaily.com.

Boehringer Ingelheim, MD Anderson to advance new cancer treatments

German pharmaceutical giant Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center are joining forces to form a new virtual research and development center (R&D center) to rapidly advance new cancer treatments, covering various forms of the disease including lung and gastrointestinal cancers. The new virtual R&D center is expected to facilitate the […]

The post Boehringer Ingelheim, MD Anderson to advance new cancer treatments appeared first on PharmaNewsDaily.com.

Scroll To Top